



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000, E:info@viyash.com

E: investorrelations@sequent.in

Website: www.sequent.in

CIN: L99999TS1985PLC196357

January 17, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Scrip code: 512529

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip code: SEQUENT

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/ Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations, we wish to inform that following the amalgamation of Symed Labs Ltd (“Symed”) with Viyash Lifesciences Pvt. Ltd. (“Viyash”) and, subsequently, Viyash's amalgamation with the Company pursuant to Composite Scheme of Amalgamation, and on the request of the Company, Crisil Limited (“Crisil”) has withdrawn the rating assigned to the various credit facilities availed by Symed in accordance with Crisil's policy on withdrawal of ratings.

A copy of Crisil's Press Release dated January 16, 2026, as published on its website is enclosed herewith.

Kindly take the same on record.

Yours faithfully,

For Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl: As above

Rating Rationale

January 16, 2026 | Mumbai

Symed Labs Limited

Ratings Withdrawn

Rating Action

Total Bank Loan Facilities Rated	Rs.182 Crore
Long Term Rating	Withdrawn (Crisil A/Watch Developing)
Short Term Rating	Withdrawn (Crisil A1)

Note: None of the Directors on Crisil Ratings Limited's Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings.

1 crore = 10 million

Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

Crisil Ratings has **withdrawn** its ratings on the bank facilities of Symed Labs Ltd (Symed), following the amalgamation of Symed with Viyash Lifesciences Pvt Ltd (Viyash) and, subsequently, Viyash's amalgamation with Sequent Scientific Ltd (Sequent). On November 27, 2025, the amalgamation of Symed with Viyash is deemed effective for Symed, and subsequently, on December 16, 2025, the amalgamation of Viyash with Sequent is deemed effective for Viyash—following the filing of the National Company Law Tribunal order dated November 18, 2025, Hyderabad Bench, sanctioning the scheme of arrangement, with the Registrar of Companies by Symed and Viyash respectively. Consequent to the amalgamation, Symed has ceased to exist. The withdrawal of ratings is in accordance with Crisil Ratings' policy on withdrawal of ratings.

Analytical Approach

Crisil Ratings has applied its policy on withdrawal of ratings.

About the Company

Incorporated in 1998 by Dr D Mohan Rao and Dr B Parthasaradi Reddy, Symed manufactures active pharmaceutical ingredients (APIs). The company has a portfolio of about 50 APIs across diverse therapeutic segments. It has four API plants and one research and development (R&D) centre (all in and around Hyderabad). All the plants are approved by the United States Food and Drug Administration (USFDA) and cater exclusively to the overseas markets.

Global private equity firm, Carlyle-backed pharmaceutical company, Viyash, took a majority stake (74%) in Symed in July 2021 and subsequently increased it to 100% in July 2024, post the acquisition of the balance stake held by Dr G Mohan Rao and Dr Parthasaradi Reddy, founders of Symed. Incorporated in 2019, the parent is a mid-tier API and formulations player. It has nine manufacturing facilities in India with a combined capacity of ~2,000 kilolitre and one formulation facility in the US. Most facilities are USFDA approved for APIs or intermediates and can service both the regulated and semi-regulated markets. Viyash was set up by Dr Hari Babu (erstwhile Global COO of Mylan and CEO of Mylan India) in partnership with Dr Srihari Raju Kalidindi (erstwhile Executive Director of Laurus Laboratories).

Incorporated in 1985, SeQuent is a leading animal health pharmaceuticals company with a global footprint, presence in formulations and API segments across multiple markets and customers. SeQuent has seven manufacturing facilities globally, five R&D centres and presence in over 100 countries. Carlyle held ~53% stake in SeQuent as on March 31, 2025.

Key Financial Indicators (Crisil Ratings-adjusted numbers)

Particulars	Unit	2025	2024
Revenue	Rs.Crore	785	709
Profit After Tax (PAT)	Rs.Crore	120	101
PAT Margin	%	15.4	14.2
Adjusted debt/adjusted networth	Times	0.03	0.18
Adjusted interest coverage	Times	36.66	20.81

Any other information: Not applicable

Note on complexity levels of the rated instrument:

Crisil Ratings` complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

Crisil Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the Crisil Ratings` complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN	Name Of Instrument	Date Of Allotment	Coupon Rate (%)	Maturity Date	Issue Size (Rs.Crore)	Complexity Levels	Rating Outstanding with Outlook
NA	Cash Credit ^{&}	NA	NA	NA	75.00	NA	Withdrawn
NA	Foreign Exchange Forward	NA	NA	NA	3.00	NA	Withdrawn
NA	Letter of Credit [^]	NA	NA	NA	20.00	NA	Withdrawn
NA	Working Capital Demand Loan %	NA	NA	NA	75.00	NA	Withdrawn
NA	Long Term Bank Facility	NA	NA	NA	9.00	NA	Withdrawn

& - Interchangeable with packing credit/packing credit in foreign currency

[^] - Includes sub-limit for SBLC for buyers credit of Rs 20 crore and Bank guarantee of Rs 2 crore

% - Includes sub-limit for export packing credit/packing credit in foreign currency of Rs 50 crore

Annexure - Rating History for last 3 Years

	Current			2026 (History)		2025		2024		2023		Start of 2023
Instrument	Type	Outstanding Amount	Rating	Date	Rating	Date	Rating	Date	Rating	Date	Rating	Rating
Fund Based Facilities	LT/ST	162.0	Withdrawn		--	20-10-25	Crisil A/Watch Developing / Crisil A1	29-10-24	Crisil A/Watch Developing / Crisil A1	04-08-23	Crisil A1 / Crisil A/Stable	Crisil A/Stable
			--		--	23-07-25	Crisil A/Watch Developing / Crisil A1		--		--	--
			--		--	24-04-25	Crisil A/Watch Developing / Crisil A1		--		--	--
			--		--	24-01-25	Crisil A/Watch Developing / Crisil A1		--		--	--
Non-Fund Based Facilities	ST	20.0	Withdrawn		--	20-10-25	Crisil A1	29-10-24	Crisil A1	04-08-23	Crisil A1	Crisil A1
			--		--	23-07-25	Crisil A1		--		--	--
			--		--	24-04-25	Crisil A1		--		--	--
			--		--	24-01-25	Crisil A1		--		--	--

All amounts are in Rs.Cr.

Annexure - Details of Bank Lenders & Facilities

Facility	Amount (Rs.Crore)	Name of Lender	Rating
Cash Credit ^{&}	75	Kotak Mahindra Bank Limited	Withdrawn
Foreign Exchange Forward	3	Kotak Mahindra Bank Limited	Withdrawn

Letter of Credit[^]	20	Kotak Mahindra Bank Limited	Withdrawn
Long Term Bank Facility	9	Kotak Mahindra Bank Limited	Withdrawn
Working Capital Demand Loan %	60	Kotak Mahindra Bank Limited	Withdrawn
Working Capital Demand Loan %	15	Kotak Mahindra Bank Limited	Withdrawn

& - Interchangeable with packing credit/packing credit in foreign currency

[^] - Includes sub-limit for SBLC for buyers credit of Rs 20 crore and Bank guarantee of Rs 2 crore

% - Includes sub-limit for export packing credit/packing credit in foreign currency of Rs 50 crore

Criteria Details

Links to related criteria

Basics of Ratings (including default recognition, assessing information adequacy)

Media Relations	Analytical Contacts	Customer Service Helpdesk
Ramkumar Uppara Media Relations Crisil Limited M: +91 98201 77907 B: +91 22 6137 3000 ramkumar.uppara@crisil.com	Anuj Sethi Senior Director Crisil Ratings Limited D:+91 44 6656 3108 anuj.sethi@crisil.com	Timings: 10.00 am to 7.00 pm Toll Free Number: 1800 267 3850 For a copy of Rationales / Rating Reports: CRISILratingdesk@crisil.com
Kartik Behl Media Relations Crisil Limited M: +91 90043 33899 B: +91 22 6137 3000 kartik.behl@crisil.com	Aditya Jhaver Director Crisil Ratings Limited D:+91 22 6137 3329 aditya.jhaver@crisil.com	
Divya Pillai Media Relations Crisil Limited M: +91 86573 53090 B: +91 22 6137 3000 divya.pillai1@ext-crisil.com	Anuj Kabra Senior Rating Analyst Crisil Ratings Limited B:+91 22 6137 3000 anuj.kabra@crisil.com	For Analytical queries Toll Free Number: 1800 266 6550 ratingsinvestordesk@crisil.com

Note for Media:

This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper/magazine/agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to Crisil Ratings. However, Crisil Ratings alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites and portals.

About Crisil Ratings Limited (A subsidiary of Crisil Limited, an S&P Global Company)

Crisil Ratings pioneered the concept of credit rating in India in 1987. With a tradition of independence, analytical rigour and innovation, we set the standards in the credit rating business. We rate the entire range of debt instruments, such as bank loans, certificates of deposit, commercial paper, non-convertible/convertible/partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 33,000 large and mid-scale corporates and financial institutions. We have also instituted several innovations in India in the rating business, including ratings for municipal bonds, partially guaranteed instruments and infrastructure investment trusts (InvITs).

Crisil Ratings Limited ('Crisil Ratings') is a wholly-owned subsidiary of Crisil Limited ('Crisil'). Crisil Ratings Limited is registered in India as a credit rating agency with the Securities and Exchange Board of India ("SEBI").

For more information, visit www.crisilratings.com

About Crisil Limited

Crisil is a leading, agile and innovative global analytics company driven by its mission of making markets function better.

It is India's foremost provider of ratings, data, research, analytics and solutions with a strong track record of growth, culture of innovation, and global footprint.

It has delivered independent opinions, actionable insights, and efficient solutions to over 100,000 customers through businesses that operate from India, the US, the UK, Argentina, Poland, China, Hong Kong and Singapore.

It is majority owned by S&P Global Inc, a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.

For more information, visit www.crisil.com

Connect with us: [TWITTER](#) | [LINKEDIN](#) | [YOUTUBE](#) | [FACEBOOK](#)

CRISIL PRIVACY NOTICE

Crisil respects your privacy. We may use your contact information, such as your name, address and email id to fulfil your request and service your account and to provide you with additional information from Crisil. For further information on Crisil's privacy policy please visit www.crisil.com.

DISCLAIMER

This disclaimer is part of and applies to each credit rating report and/or credit rating rationale ('report') provided by Crisil Ratings Limited ('Crisil Ratings'). For the avoidance of doubt, the term 'report' includes the information, ratings and other content forming part of the report. The report is intended for use only within the jurisdiction of India. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as Crisil Ratings provision or intention to provide any services in jurisdictions where Crisil Ratings does not have the necessary licenses and/or registration to carry out its business activities. Access or use of this report does not create a client relationship between Crisil Ratings and the user.

The report is a statement of opinion as on the date it is expressed, and it is not intended to and does not constitute investment advice within meaning of any laws or regulations (including US laws and regulations). The report is not an offer to sell or an offer to purchase or subscribe to any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The recipients of the report should rely on their own judgment and take their own professional advice before acting on the report in any way.

Crisil Ratings and its associates do not act as a fiduciary. The report is based on the information believed to be reliable as of the date it is published, Crisil Ratings does not perform an audit or undertake due diligence or independent verification of any information it receives and/or relies on for preparation of the report. THE REPORT IS PROVIDED ON "AS IS" BASIS. TO THE

MAXIMUM EXTENT PERMITTED BY APPLICABLE LAWS, CRISIL RATINGS DISCLAIMS WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR OTHER WARRANTIES OR CONDITIONS, INCLUDING WARRANTIES OF MERCHANTABILITY, ACCURACY, COMPLETENESS, ERROR-FREE, NON-INFRINGEMENT, NON-INTERRUPTION, SATISFACTORY QUALITY, FITNESS FOR A PARTICULAR PURPOSE OR INTENDED USAGE. In no event shall Crisil Ratings, its associates, third-party providers, as well as their directors, officers, shareholders, employees or agents be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.

The report is confidential information of Crisil Ratings and Crisil Ratings reserves all rights, titles and interest in the rating report. The report shall not be altered, disseminated, distributed, redistributed, licensed, sub-licensed, sold, assigned or published any content thereof or offer access to any third party without prior written consent of Crisil Ratings.

Crisil Ratings or its associates may have other commercial transactions with the entity to which the report pertains or its associates. Ratings are subject to revision or withdrawal at any time by Crisil Ratings. Crisil Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.

Crisil Ratings has in place a ratings code of conduct and policies for managing conflict of interest. For more detail, please refer to: <https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html>. Public ratings and analysis by Crisil Ratings, as are required to be disclosed under the Securities and Exchange Board of India regulations (and other applicable regulations, if any), are made available on its websites, www.crisilratings.com and <https://www.ratingsanalytica.com> (free of charge). Crisil Ratings shall not have the obligation to update the information in the Crisil Ratings report following its publication although Crisil Ratings may disseminate its opinion and/or analysis. Reports with more detail and additional information may be available for subscription at a fee. Rating criteria by Crisil Ratings are available on the Crisil Ratings website, www.crisilratings.com. For the latest rating information on any company rated by Crisil Ratings, you may contact the Crisil Ratings desk at crisilratingdesk@crisil.com, or at (0091) 1800 267 3850.

Crisil Ratings shall have no liability, whatsoever, with respect to any copies, modifications, derivative works, compilations or extractions of any part of this [report/ work products], by any person, including by use of any generative artificial intelligence or other artificial intelligence and machine learning models, algorithms, software, or other tools. Crisil Ratings takes no responsibility for such unauthorized copies, modifications, derivative works, compilations or extractions of its [report/ work products] and shall not be held liable for any errors, omissions of inaccuracies in such copies, modifications, derivative works, compilations or extractions. Such acts will also be in breach of Crisil Ratings' intellectual property rights or contrary to the laws of India and Crisil Ratings shall have the right to take appropriate actions, including legal actions against any such breach.

Crisil Ratings uses the prefix 'PP-MLD' for the ratings of principal-protected market-linked debentures (PPMLD) with effect from November 1, 2011, to comply with the SEBI circular, "Guidelines for Issue and Listing of Structured Products/Market Linked Debentures". The revision in rating symbols for PPMLDs should not be construed as a change in the rating of the subject instrument. For details on Crisil Ratings' use of 'PP-MLD' please refer to the notes to Rating scale for Debt Instruments and Structured Finance Instruments at the following link: <https://www.crisilratings.com/en/home/our-business/ratings/credit-ratings-scale.html>